Recommandations d’utilisation des biosimilaires de l’érythropoïétine (EPO). Propositions de la Société de néphrologie, de la Société francophone de dialyse et de la Société de néphrologie pédiatrique-Reference-Cited by-同舟云学术

Recommandations d’utilisation des biosimilaires de l’érythropoïétine (EPO). Propositions de la Société de néphrologie, de la Société francophone de dialyse et de la Société de néphrologie pédiatrique

Published:2009-02 Issue:1 Volume:5 Page:61-66
ISSN:1769-7255
Container-title:Néphrologie & Thérapeutique
language:fr
Short-container-title:Néphrologie & Thérapeutique

Author:

Bouchet Jean-Louis,Brunet Philippe,Canaud Bernard,Chanliau Jacques,Combe Christian,Deray Gilbert,Houillier Pascal,Kourilsky Olivier,Ledneva Elena,Niaudet Patrick,Ortiz Jean-Paul,Pavlovic Mira,Ryckelynck Jean-Philippe,Singlas Eric,Verhelst David

Publisher

Elsevier BV

Subject

Nephrology

Reference5 articles.

1. Position statement regardind usage of biosimilars: position paper of the Société de néphrologie, Société francophone de dialyse and de Société de néphrologie pédiatrique;Nephrol Ther,2006

2. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. CHMP/BWP/49 348/2005.

3. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non clinical and clinical issues. CHMP/BMWP/42 832/2005.

4. Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non clinical and clinical issues; guidance on biosimilar medicinal products containing recombinant erythropoietin. CHMP/94 526/2005.

5. Pure red cell aplasie due to follow-on epoetin;Keithy-Reddy;Kidney Int,2008

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential Impact of Subsequent Entry Biologics in Nephrology Practice in Canada;Canadian Journal of Kidney Health and Disease;2014-01-01

2. Pharmacovigilance and biosimilars: considerations, needs and challenges;Expert Opinion on Biological Therapy;2013-03-26

3. Colony stimulating factors (CSF) biosimilars. Progress?;Targeted Oncology;2012-01-17

4. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation;Haematologica;2011-06-30

5. Les facteurs de croissance (CSF) biosimilaires : une avancée ?;Oncologie;2011-05